Company Profiles

driven by the PitchBook Platform

Lux Biosciences

Lux Biosciences
2006 FOUNDED
OOB STATUS
11-20 EMPLOYEES
Out of Business LATEST DEAL TYPE
7 INVESTORS
Description

Developer of medications and drugs designed to treat ophthalmic diseases. The company's medications and drugs include LX201, silicone matrix ocular implant and Luveniq, an oral form of drug inhibitor voclosporin, enabling healthcare professionals to treat serious ophthalmic diseases.

Website
Ownership Status
Out of Business
Financing Status
Formerly VC-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
Harborside Financial Center Plaza 10
14th Floor
Jersey City, NJ 07302
United States

+1 (201) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Lux Biosciences’s full profile, request a free trial.

Lux Biosciences Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Out of Business 01-Jul-2013 00000 Completed Out of Business
9. Convertible Debt 23-Feb-2012 0000 00000 Completed Generating Revenue
8. Convertible Debt 12-Dec-2011 000 00000 Completed Startup
7. Convertible Debt 14-Jul-2011 000 00000 Completed Startup
6. Convertible Debt 18-Mar-2011 000 00000 Completed Startup
5. Convertible Debt 20-Dec-2010 000 00000 Completed Startup
4. Early Stage VC (Series B) 30-Oct-2009 0000 00000 00000 Completed Startup
3. Debt - General 16-Jun-2009 00.00 000.00 Completed Startup
2. Convertible Debt 18-Nov-2008 $10M $59M Completed Startup
1. Early Stage VC (Series A) 19-Jul-2006 $49M $49M 0000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Lux Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00 00 00 00 00 00.000
Series A 00,000,000 00.000000 00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

Lux Biosciences Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
International Biotechnology Trust Mutual Fund Minority 000 0000 000000 0
Hatteras Venture Partners Venture Capital Minority 000 0000 000000 0
HBM Healthcare Investments Venture Capital Minority 000 0000 000000 0
HBM Partners Asset Manager Minority 000 0000 000000 0
Novo Holdings Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Lux Biosciences Executive Team (4)

Name Title Board
Seat
Contact
Info
Dean Mitchell President, Chief Executive Officer and Board Member
Eddy Anglade MD Co-Founder & Chief Medical Officer

2 Former Executives

You’re viewing 2 of 4 executives. Get the full list »

Lux Biosciences Board Members (6)

Name Representing Role Since Contact
Info
Axel Bolte Lux Biosciences Board Member 000 0000
David Schnell MD Prospect Venture Partners Board Member 000 0000
Paul Chaney Lux Biosciences Board Member 000 0000
Thomas Dyrberg Lux Biosciences Board Member 000 0000

2 Former Board Members

You’re viewing 4 of 6 board members. Get the full list »
Questions or concerns about this profile? Reach out to website-support@pitchbook.com